Cargando…

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination

Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on histor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mengesha, Bethlehem, Asenov, Asen G., Hirsh-Raccah, Bruria, Amir, Offer, Pappo, Orit, Asleh, Rabea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024648/
https://www.ncbi.nlm.nih.gov/pubmed/35455324
http://dx.doi.org/10.3390/vaccines10040575
_version_ 1784690654049206272
author Mengesha, Bethlehem
Asenov, Asen G.
Hirsh-Raccah, Bruria
Amir, Offer
Pappo, Orit
Asleh, Rabea
author_facet Mengesha, Bethlehem
Asenov, Asen G.
Hirsh-Raccah, Bruria
Amir, Offer
Pappo, Orit
Asleh, Rabea
author_sort Mengesha, Bethlehem
collection PubMed
description Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine.
format Online
Article
Text
id pubmed-9024648
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90246482022-04-23 Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination Mengesha, Bethlehem Asenov, Asen G. Hirsh-Raccah, Bruria Amir, Offer Pappo, Orit Asleh, Rabea Vaccines (Basel) Case Report Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine. MDPI 2022-04-08 /pmc/articles/PMC9024648/ /pubmed/35455324 http://dx.doi.org/10.3390/vaccines10040575 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Mengesha, Bethlehem
Asenov, Asen G.
Hirsh-Raccah, Bruria
Amir, Offer
Pappo, Orit
Asleh, Rabea
Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title_full Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title_fullStr Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title_full_unstemmed Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title_short Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
title_sort severe acute myocarditis after the third (booster) dose of mrna covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024648/
https://www.ncbi.nlm.nih.gov/pubmed/35455324
http://dx.doi.org/10.3390/vaccines10040575
work_keys_str_mv AT mengeshabethlehem severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination
AT asenovaseng severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination
AT hirshraccahbruria severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination
AT amiroffer severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination
AT pappoorit severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination
AT aslehrabea severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination